ECSS
MIRM icon

Eurizon Capital SGR SpA’s Mirum Pharmaceuticals MIRM Stock Holding History

Eurizon Capital SGR SpA’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-800
Closed -$70.7K – 1268
2026
Q1 		$70.7K Buy
800
+400
+100% +$37.6K ﹤0.01% 966
2025
Q4 		$31.5K Buy
+400
New +$28.7K ﹤0.01% 935

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's MIRM Position: Q2 2026 in Review

Eurizon Capital SGR SpA sold out of Mirum Pharmaceuticals (MIRM) in Q2 2026, closing a stake of 800 shares — an estimated $70.7K sold.

Eurizon Capital SGR SpA first reported a position in MIRM in Q4 2025 and held it in 2 quarters. The position peaked at $70.7K in Q1 2026. 326 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Eurizon Capital SGR SpA reported no remaining Mirum Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Eurizon Capital SGR SpA sold 800 Mirum Pharmaceuticals shares in Q2 2026, an estimated $70.7K.
  • Eurizon Capital SGR SpA first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Eurizon Capital SGR SpA's Mirum Pharmaceuticals position peaked at $70.7K in Q1 2026.
  • 326 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.